HANSOH PHARMA (03692.HK): AilsynBio Deal Gives Access to AI Platform for Oral Cyclic Peptides

NewTimeSpace News: On 13 November 2026, HANSOH PHARMA (03692.HK) said in a voluntary announcement that its wholly-owned subsidiary Hansoh (Shanghai) Healthtech Co., Ltd. entered into a collaboration and development agreement with AilsynBio Limited.

Under the agreement, the Company obtains a licence to use AilsynBio's AI platform within the agreed scope to discover novel oral cyclic peptide candidates, and has the right to select targets, acquire intellectual property rights in the corresponding programmes and lead subsequent development. AilsynBio is eligible to receive aggregate payments of up to RMB 317 million and single-digit percentage royalties on potential future net sales of products developed under the programmes.

AilsynBio is a next-generation AI-native biotechnology company headquartered in Hong Kong that focuses on innovative therapies built around oral cyclic peptides, the announcement said, adding that its closed-loop discovery platform combines in-house AI with experimental validation to extend the reach of peptide medicines and deliver differentiated therapies for unmet medical needs.

The announcement said payments under the agreement are expected to be recognised as research and development expenditure. Assuming the transaction falls within the meaning of "transaction" under Chapter 14 of the Listing Rules, all applicable percentage ratios for the payable amounts are below 5%, so the transaction is not a discloseable transaction and is not a connected transaction under Chapter 14A.